biostudies-literatureUnknownWisch JKNIA NIH HHSDown syndrome is characterized by triplication of chromosome 21, leading to early-onset Alzheimer disease pathology, with nearly all individuals with Down syndrome developing amyloid and tau pathology. In the new era of amyloid modifying therapies, it is vital to identify early biomarkers for Alzheimer disease (AD) pathology in Down syndrome. Striatal amyloid may begin to accumulate sooner than cortical amyloid in Down syndrome. Tau phosphorylation at specific sites, including 217, can be quantified in plasma and may represent an important mechanistic step in the development of tau pathology. This study had two aims: 1. To compare the relative age at increase of multiple biomarkers (cortical amyloid, striatal amyloid, plasma pTau217 and summary tau pathology) 2. To test whether plasma pTauBrain : a journal of neurologyawaf418https://www.ebi.ac.uk/biostudies/studies/S-EPMC12917769biostudies-literatureImaging and plasma biomarkers for pathological accumulation in Down syndrome.PMC12917769U01 AG051412U01 AG051406U19 AG068054Petersen MSchlachetzki ZZaman SLai FTudorascu DRosas HDAnces BMSchmitt FALott ITHanden BLIbanez LLee JHMapstone MCohen ADHom CChristian BTKrinsky-McHale SJPtomey LRafii MSKennedy JTBurns JMWisch JKHarp JPHartley SJiao ZHead EfalseImaging and plasma biomarkers for pathological accumulation in Down syndrome.Down syndrome is characterized by triplication of chromosome 21, leading to early-onset Alzheimer disease pathology, with nearly all individuals with Down syndrome developing amyloid and tau pathology. In the new era of amyloid modifying therapies, it is vital to identify early biomarkers for Alzheimer disease (AD) pathology in Down syndrome. Striatal amyloid may begin to accumulate sooner than cortical amyloid in Down syndrome. Tau phosphorylation at specific sites, including 217, can be quantified in plasma and may represent an important mechanistic step in the development of tau pathology. This study had two aims: 1. To compare the relative age at increase of multiple biomarkers (cortical amyloid, striatal amyloid, plasma pTau217 and summary tau pathology) 2. To test whether plasma pTau2025-01-01T00:00:00Z2025 Nov2026-07-16T09:44:51.924Z2026-07-09T10:47:19.193ZS-EPMC129177694120562310.1093/brain/awaf418